Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,276
archived clinical trials in
Pancreatic Cancer

Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or Peritoneal Surface Cancer
The Effect of Negative Pressure Therapy on Incisional Surgical Site Infections
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or Peritoneal Surface Cancer
The Effect of Negative Pressure Therapy on Incisional Surgical Site Infections
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Collecting Solid Tumor Tissue to Identify New Treatments
Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Collecting Solid Tumor Tissue to Identify New Treatments
Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
A Phase II Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients With Borderline Resectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
A Phase II Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients With Borderline Resectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer
Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer at Moffitt Cancer Center and Lehigh Valley Hospital
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer
Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer at Moffitt Cancer Center and Lehigh Valley Hospital
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer
Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer at Moffitt Cancer Center and Lehigh Valley Hospital
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Health Network
mi
from
Allentown, PA
Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer
Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer at Moffitt Cancer Center and Lehigh Valley Hospital
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Health Network
mi
from
Allentown, PA
Click here to add this to my saved trials
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Trial Comparing Metal Versus Plastic Stents for Preoperative Biliary Decompression
Multicenter Randomized Trial Comparing Covered Metal and Plastic Stents for Preoperative Biliary Decompression in Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Hospital
mi
from
Orlando, FL
Trial Comparing Metal Versus Plastic Stents for Preoperative Biliary Decompression
Multicenter Randomized Trial Comparing Covered Metal and Plastic Stents for Preoperative Biliary Decompression in Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer
A Phase II Trial of Gemcitabine and Erlotinib (GE) Plus Proton-chemotherapy (PCT) and Capox for Locally Advanced Pancreatic Cancer (LAPC)
Status: Enrolling
Updated:  12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer
A Phase II Trial of Gemcitabine and Erlotinib (GE) Plus Proton-chemotherapy (PCT) and Capox for Locally Advanced Pancreatic Cancer (LAPC)
Status: Enrolling
Updated: 12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Minocycline Study in Pancreatic Cancer Patients
A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden for Pancreatic Cancer Patients
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Minocycline Study in Pancreatic Cancer Patients
A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden for Pancreatic Cancer Patients
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Scottsdale, AZ
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
HonorHealth
mi
from
Scottsdale, AZ
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
HonorHealth
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
University of Michighan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
University of Michighan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated:  12/31/1969
Washington University
mi
from
Saint Louis, MO
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: Enrolling
Updated: 12/31/1969
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma
Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma
Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Alabama Oncology
mi
from
Birmingham, AL
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Alabama Oncology
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
UCLA Medical Center
mi
from
Santa Monica, CA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
UCLA Medical Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Sarasota, FL
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Sarasota, FL
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Indiana University Health Goshen Center For Cancer Care
mi
from
Goshen, IN
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Indiana University Health Goshen Center For Cancer Care
mi
from
Goshen, IN
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Cornell University
mi
from
New York, NY
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Vanderbilt
mi
from
Nashville, TN
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Vanderbilt
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
UT Southwestern
mi
from
Dallas, TX
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
UT Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Northwest Medical Specialties
mi
from
Tacoma, WA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Northwest Medical Specialties
mi
from
Tacoma, WA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
San Diego Pacific Oncology and Hematology Associates
mi
from
Encinitas, CA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
San Diego Pacific Oncology and Hematology Associates
mi
from
Encinitas, CA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Southern California (USC)
mi
from
Los Angeles, CA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Southern California (USC)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Parkview Research Center
mi
from
Fort Wayne, IN
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Parkview Research Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Greenville Health System, Institute for Translational Oncology Research
mi
from
Greenville, SC
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Greenville Health System, Institute for Translational Oncology Research
mi
from
Greenville, SC
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
Phase II Feasibility Study of FOLFIRINOX-Losartan Followed by Accelerated Short Course Radiation Therapy With Capecitabine for Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
Phase II Feasibility Study of FOLFIRINOX-Losartan Followed by Accelerated Short Course Radiation Therapy With Capecitabine for Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Arizona Cancer Center
mi
from
Tucson, AZ
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Sutter Institute for Medical Research
mi
from
Sacramento, CA
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Sutter Institute for Medical Research
mi
from
Sacramento, CA
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
The Stamford Hospital
mi
from
Stamford, CT
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
The Stamford Hospital
mi
from
Stamford, CT
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Boca Raton Regional Hospital
mi
from
Boca Raton, FL
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Boca Raton Regional Hospital
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
USF / Tampa General
mi
from
Tampa, FL
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
USF / Tampa General
mi
from
Tampa, FL
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Illinois Cancer Specialists
mi
from
Arlington Heights, IL
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Illinois Cancer Specialists
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Indiana University Health Goshen Center For Cancer Care
mi
from
Goshen, IN
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana University Health Goshen Center For Cancer Care
mi
from
Goshen, IN
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of Kansas Cancer Center
mi
from
Westwood, KA
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of Kansas Cancer Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
University of Louisville
mi
from
Louisville, KY
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials